DE60011794D1 - Verwendung von docetaxel für die behandlung von hepatozelluläre krebs - Google Patents

Verwendung von docetaxel für die behandlung von hepatozelluläre krebs

Info

Publication number: DE60011794D1
Authority: DE; Germany
Prior art keywords: docetaxel; hepatocellular cancer; treating hepatocellular; hepatocellular carcinoma; treating
Prior art date: 1999-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60011794T

Other languages

English (en)

Other versions

DE60011794T2 (de

Inventor

Chin-Wen Chi

Heng-Liang Lin

Tsung-Yun Liu

Wing-Yiu Lui

Gar-Yang Chau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharma SA

Original Assignee

Aventis Pharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-31

Filing date

2000-08-29

Publication date

2004-07-29

2000-08-29 Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA

2004-07-29 Publication of DE60011794D1 publication Critical patent/DE60011794D1/de

2005-07-14 Application granted granted Critical

2005-07-14 Publication of DE60011794T2 publication Critical patent/DE60011794T2/de

2020-08-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 3
229960003668 docetaxel Drugs 0.000 title abstract 3
206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 3
208000014018 liver neoplasm Diseases 0.000 title 1
231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 2
229930012538 Paclitaxel Natural products 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

DE60011794T 1999-08-31 2000-08-29 Verwendung von docetaxel für die behandlung von hepatozelluläre krebs Expired - Lifetime DE60011794T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9920548		1999-08-31
GBGB9920548.6A GB9920548D0 (en)	1999-08-31	1999-08-31	Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en)	1999-08-31	2000-08-29	Use of docetaxel for treating hepatocellular carcinoma

Publications (2)

Publication Number	Publication Date
DE60011794D1 true DE60011794D1 (de)	2004-07-29
DE60011794T2 DE60011794T2 (de)	2005-07-14

Family

ID=10860081

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60011794T Expired - Lifetime DE60011794T2 (de)	1999-08-31	2000-08-29	Verwendung von docetaxel für die behandlung von hepatozelluläre krebs

Country Status (34)

Country	Link
US (2)	US20030158249A1 (de)
EP (1)	EP1214061B1 (de)
JP (1)	JP4866522B2 (de)
KR (1)	KR100670416B1 (de)
CN (1)	CN1174748C (de)
AT (1)	ATE269700T1 (de)
AU (1)	AU777583B2 (de)
BG (1)	BG65913B1 (de)
BR (1)	BR0013625A (de)
CA (1)	CA2382294C (de)
CZ (1)	CZ301378B6 (de)
DE (1)	DE60011794T2 (de)
DK (1)	DK1214061T3 (de)
EA (1)	EA004804B1 (de)
EE (1)	EE05124B1 (de)
ES (1)	ES2218223T3 (de)
GB (1)	GB9920548D0 (de)
HK (1)	HK1048944B (de)
HR (1)	HRP20020171A2 (de)
HU (1)	HU228861B1 (de)
IL (2)	IL147489A0 (de)
ME (1)	ME00624B (de)
MX (1)	MXPA02002041A (de)
NO (1)	NO328527B1 (de)
NZ (1)	NZ517604A (de)
PL (1)	PL212612B1 (de)
PT (1)	PT1214061E (de)
RS (1)	RS50148B (de)
SI (1)	SI1214061T1 (de)
SK (1)	SK286378B6 (de)
TW (1)	TW589180B (de)
UA (1)	UA72927C2 (de)
WO (1)	WO2001015675A2 (de)
ZA (1)	ZA200201408B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1268619C (zh) *	2003-05-08	2006-08-09	上海迪赛诺化学制药有限公司	多烯紫杉醇三水化合物的制备方法
WO2005061474A1 (en) *	2003-12-12	2005-07-07	Quiral Química Do Brasil	Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) *	2004-07-09	2008-11-11	Robert Sabin	Anti tumor compositions and methods of use
US8034765B2 (en)	2005-08-31	2011-10-11	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
ES2784794T3 (es) *	2005-08-31	2020-10-01	Abraxis Bioscience Llc	Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) *	2006-09-28	2008-04-03	Robert Sabin	Method of manufacturing anti-tumor and anti-viral compositions
WO2009007992A2 (en) *	2007-04-20	2009-01-15	Sun Pharmaceutical Industries Limited	Pharmaceutical composition produced by microprecipitation
FR2917088B1 (fr) *	2007-06-08	2009-09-04	Aventis Pharma Sa	Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) *	2008-11-19	2013-09-24	Ben Venue Laboratories, Inc.	Parenteral formulations comprising sugar-based esters and ethers
LT2552438T (lt)	2010-03-26	2016-09-26	Abraxis Bioscience, Llc	Hepatoceliulinės karcinomos gydymo būdai
JP5824511B2 (ja) *	2010-05-03	2015-11-25	テイコクファーマユーエスエーインコーポレーテッド	非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
US8842114B1 (en)	2011-04-29	2014-09-23	Nvidia Corporation	System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2976912A1 (en) *	2015-02-17	2016-08-25	Mallinckrodt Llc	Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) *	1988-04-06	1990-11-16	Rhone Poulenc Sante	Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) *	1991-12-27	1996-08-06	Merck & Co., Inc.	Controlled release nifedipine delivery device
DE69324504T2 (de) *	1993-01-19	1999-08-26	Warner-Lambert Co.	Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5801029A (en) *	1993-02-16	1998-09-01	Onyx Pharmaceuticals, Inc.	Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1999000113A1 (en) *	1997-06-27	1999-01-07	Vivorx Pharmaceuticals, Inc.	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5436243A (en) *	1993-11-17	1995-07-25	Research Triangle Institute Duke University	Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) *	1994-04-25	1996-05-24	Rhone Poulenc Rorer Sa	Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) *	1994-07-08	1996-08-23	Rhone Poulenc Rorer Sa	Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en)	1995-10-26	1999-10-19	Baker Norton Pharmaceuticals, Inc.	Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) *	1995-12-22	1998-01-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) *	1996-12-30	2003-01-07	Bone Care International, Inc.	Method of treating hyperproliferative diseases using active vitamin D analogues
DE69737510T2 (de) *	1996-12-30	2007-12-06	Battelle Memorial Institute, Columbus	Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
JP3775780B2 (ja) *	1997-09-18	2006-05-17	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	薬剤の経口的バイオアベイラビリテイを向上させるための縮合イミダゾール誘導体
KR20010031501A (ko) *	1997-10-31	2001-04-16	추후제출	5-알파 환원효소 활성을 조절하는 방법 및 조성물
UA73092C2 (uk) *	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Таблетка з ентеросолюбільним покриттям і спосіб її приготування
IL143901A0 (en) *	1998-12-23	2002-04-21	Searle & Co	Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
GB9909925D0 (en) *	1999-04-29	1999-06-30	Pharmacia & Upjohn Spa	Combined preparations comprising anthracycline derivatives
MX2007014329A (es) *	2005-12-13	2008-03-19	Teva Pharma	Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.

1999
- 1999-08-31 GB GBGB9920548.6A patent/GB9920548D0/en not_active Ceased
- 1999-09-22 TW TW088115041A patent/TW589180B/zh not_active IP Right Cessation
2000
- 2000-08-29 NZ NZ517604A patent/NZ517604A/en not_active IP Right Cessation
- 2000-08-29 PT PT00964144T patent/PT1214061E/pt unknown
- 2000-08-29 IL IL14748900A patent/IL147489A0/xx active IP Right Grant
- 2000-08-29 HU HU0203197A patent/HU228861B1/hu not_active IP Right Cessation
- 2000-08-29 PL PL353198A patent/PL212612B1/pl unknown
- 2000-08-29 MX MXPA02002041A patent/MXPA02002041A/es active IP Right Grant
- 2000-08-29 SI SI200030478T patent/SI1214061T1/xx unknown
- 2000-08-29 RS YUP-114/02A patent/RS50148B/sr unknown
- 2000-08-29 WO PCT/EP2000/008782 patent/WO2001015675A2/en not_active Ceased
- 2000-08-29 EA EA200200313A patent/EA004804B1/ru not_active IP Right Cessation
- 2000-08-29 EP EP00964144A patent/EP1214061B1/de not_active Expired - Lifetime
- 2000-08-29 ES ES00964144T patent/ES2218223T3/es not_active Expired - Lifetime
- 2000-08-29 DE DE60011794T patent/DE60011794T2/de not_active Expired - Lifetime
- 2000-08-29 EE EEP200200087A patent/EE05124B1/xx not_active IP Right Cessation
- 2000-08-29 HR HR20020171A patent/HRP20020171A2/hr not_active Application Discontinuation
- 2000-08-29 SK SK271-2002A patent/SK286378B6/sk not_active IP Right Cessation
- 2000-08-29 AU AU75168/00A patent/AU777583B2/en not_active Ceased
- 2000-08-29 CA CA002382294A patent/CA2382294C/en not_active Expired - Fee Related
- 2000-08-29 AT AT00964144T patent/ATE269700T1/de active
- 2000-08-29 DK DK00964144T patent/DK1214061T3/da active
- 2000-08-29 ME MEP-2009-78A patent/ME00624B/me unknown
- 2000-08-29 CN CNB008114501A patent/CN1174748C/zh not_active Expired - Fee Related
- 2000-08-29 HK HK03101197.6A patent/HK1048944B/zh not_active IP Right Cessation
- 2000-08-29 CZ CZ20020739A patent/CZ301378B6/cs not_active IP Right Cessation
- 2000-08-29 UA UA2002021546A patent/UA72927C2/uk unknown
- 2000-08-29 BR BR0013625-5A patent/BR0013625A/pt not_active Application Discontinuation
- 2000-08-29 KR KR1020027002446A patent/KR100670416B1/ko not_active Expired - Fee Related
- 2000-08-29 JP JP2001519889A patent/JP4866522B2/ja not_active Expired - Fee Related
2002
- 2002-01-06 IL IL147489A patent/IL147489A/en not_active IP Right Cessation
- 2002-02-19 ZA ZA200201408A patent/ZA200201408B/xx unknown
- 2002-02-20 NO NO20020829A patent/NO328527B1/no not_active IP Right Cessation
- 2002-02-27 US US10/083,565 patent/US20030158249A1/en not_active Abandoned
- 2002-02-28 BG BG106460A patent/BG65913B1/bg unknown
2007
- 2007-06-12 US US11/761,512 patent/US20080045584A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RS50148B (sr)	2009-05-06
US20030158249A1 (en)	2003-08-21
US20080045584A1 (en)	2008-02-21
HK1048944B (zh)	2005-04-22
BG65913B1 (bg)	2010-05-31
EP1214061A2 (de)	2002-06-19
AU777583B2 (en)	2004-10-21
MEP7809A (en)	2011-12-20
JP2003508427A (ja)	2003-03-04
PL353198A1 (en)	2003-11-03
CZ2002739A3 (cs)	2002-06-12
EA004804B1 (ru)	2004-08-26
PT1214061E (pt)	2004-09-30
CN1372466A (zh)	2002-10-02
HUP0203197A3 (en)	2005-01-28
ZA200201408B (en)	2003-07-30
CA2382294A1 (en)	2001-03-08
CZ301378B6 (cs)	2010-02-03
KR20020060166A (ko)	2002-07-16
NO328527B1 (no)	2010-03-08
PL212612B1 (pl)	2012-10-31
MXPA02002041A (es)	2002-08-20
WO2001015675A2 (en)	2001-03-08
HK1048944A1 (en)	2003-04-25
DE60011794T2 (de)	2005-07-14
NZ517604A (en)	2004-04-30
HRP20020171A2 (en)	2004-02-29
JP4866522B2 (ja)	2012-02-01
IL147489A (en)	2006-06-11
YU11402A (sh)	2005-07-19
GB9920548D0 (en)	1999-11-03
ATE269700T1 (de)	2004-07-15
AU7516800A (en)	2001-03-26
NO20020829D0 (no)	2002-02-20
HU228861B1 (hu)	2013-06-28
EE200200087A (et)	2003-04-15
HUP0203197A2 (hu)	2003-01-28
CA2382294C (en)	2008-06-03
IL147489A0 (en)	2002-08-14
SK2712002A3 (en)	2002-07-02
KR100670416B1 (ko)	2007-01-17
TW589180B (en)	2004-06-01
ME00624B (me)	2011-12-20
EA200200313A1 (ru)	2002-08-29
UA72927C2 (uk)	2005-05-16
SK286378B6 (sk)	2008-08-05
NO20020829L (no)	2002-02-20
BG106460A (bg)	2002-09-30
WO2001015675A3 (en)	2001-09-20
ES2218223T3 (es)	2004-11-16
BR0013625A (pt)	2002-05-14
DK1214061T3 (da)	2004-11-01
SI1214061T1 (en)	2004-12-31
EE05124B1 (et)	2009-02-16
EP1214061B1 (de)	2004-06-23
CN1174748C (zh)	2004-11-10

Publication	Publication Date	Title
DE60011794D1 (de)	2004-07-29	Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
DE50310516D1 (de)	2008-10-30	Fredericamycin-derivate
GB0223038D0 (en)	2002-11-13	Therapeutic compounds
ATE450265T1 (de)	2009-12-15	Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
DE60231804D1 (de)	2009-05-14	Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE415962T1 (de)	2008-12-15	Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE305300T1 (de)	2005-10-15	Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
EP1231914A4 (de)	2004-04-14	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE373474T1 (de)	2007-10-15	Substituierte 2-aminotetraline zur behandlung von depressionen
DE69902523D1 (de)	2002-09-19	Verwendung von erythropoietin zur behandlung von multiple myelom
DE60313603D1 (de)	2007-06-14	Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
NO20050640L (no)	2005-03-22	Rutenium anticancer komplekser
DK1438034T3 (da)	2008-12-01	Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE517617T1 (de)	2011-08-15	Behandlung von parkinson erkrankung mit kape
ATE359808T1 (de)	2007-05-15	Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60229414D1 (de)	2008-11-27	Verwendung von aplidine in der behandlung von pankreaskrebs
ATE406171T1 (de)	2008-09-15	Aplidine zur behandlung von multiplem myelom
DE60131968D1 (de)	2008-01-31	PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE302009T1 (de)	2005-09-15	Ubichinon qn zur behandlung von migräneschmerzen
ATE397924T1 (de)	2008-07-15	Satraplatin zur behandlung von resistenten oder refrkatären tumoren
DE60006284D1 (de)	2003-12-04	Arzneimittel zur behandlung konvulsivischer zustände
NO20051444L (no)	2005-05-19	Medikament inneholdende disorazoler og derivater av disse for behandling av benigne og maligne tumorsykdommer.
DE50105253D1 (de)	2005-03-10	Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE50211837D1 (de)	2008-04-17	Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren

Legal Events

Date	Code	Title	Description
2006-10-26	8328	Change in the person/name/address of the agent	Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN
2009-07-30	8328	Change in the person/name/address of the agent	Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC